

The background features a complex, abstract design. On the right side, there are several overlapping spheres and cylindrical forms. One sphere has a grid of small cubes on its surface, while another has a pattern of small, dark, irregular shapes. A large, curved, ribbed structure, resembling a DNA helix or a modern architectural element, curves around the right side. The left side is dominated by a solid black vertical bar. The central text is contained within a white rectangular area that has a slight drop shadow, giving it a three-dimensional appearance as if it's floating or attached to the background.

Member Companies

the power of #polishbiotech

bio
forum

Związek Firm Biotechnologicznych

Representation

OF THE BIOTECH SECTOR

BioForum was established in 2021 in response to the real needs of biotechnology companies collaborating with **CEBioForum** – a platform that for more than 20 years has served as a key meeting point, knowledge-exchange hub, and development space for stakeholders involved in the commercialization of bio-innovations. The creation of the Association was a natural step forward: moving from dialogue and networking toward the effective representation of the sector's interests – both in Poland and at the level of the European Union.

WHAT MAKES BIOFORUM UNIQUE

BioForum's uniqueness stems from its structure. Alongside companies engaged in biotechnology activities, it also brings together:

- commercial business support organizations (including law firms, advisors, and consultants),
- non-commercial ecosystem partners, including universities and research institutions.

This combination is rare in the market and provides members with:

- broad cross-sector collaboration,
- practical exchange of experience,
- strong scientific and substantive support.

PROMOTION AND PARTNERSHIPS

Greater visibility, easier market access, and entry to EU and US markets – without having to act alone.

Promotional and International Support

- Promotional and informational support for BioForum Members during international trade fairs and industry events, including:
- BIO International Convention (USA)
- BIO-Europe
- Swiss Biotech Day
- Prague.bio Conference
- Life Sciences Baltics
- Nordic Life Science Days
- Lithuania-Poland Life Science & Biotech Ecosystems Summit other key sector events.
- Participation in European and global industry conferences under the BioForum banner, with the possibility of delegating representatives from member companies.
- Comprehensive organization and coordination of participation in international events (including logistics, registrations, visibility, and networking support).

NETWORKING AND VISIBILITY

International networking and direct connections with:

- business partners,
- distributors,
- investors and venture capital funds.

Preferential participation conditions for CEBioForum - the largest annual biotechnology industry event in Central and Eastern Europe.

Promotion of member companies through:

- press conferences,
- meetings with industry and international media,
- presence at key sector events.

EXPERT SUPPORT AND RECOMMENDATIONS

- Access to trusted industry experts when institutions, partners, or
- event organizers seek recommendations for qualified specialists.
- Recommendations of experts in areas such as:
- regulatory affairs and reimbursement,
- clinical research,
- technology transfer,
- financing,
- commercialization and business scaling.
- Substantive support for member companies in their interactions with international partners and public institutions.

BRIDGING SCIENCE AND BUSINESS

- Support in establishing industry-science collaboration.
- Access to the resources and expertise of universities and research institutions.
- Ongoing industry monitoring covering:
 - legislative and regulatory changes,
 - available funding opportunities and grants,
 - scientific conferences and industry events (provided in the form of a regularly updated database).
- BioForum member working groups and jointly developed industry position papers.
- Support in recruiting specialists through the Biotech Talents platform.
- Reports and analyses of the biotechnology market.

STRATEGIC INITIATIVES

A tangible impact on the regulatory environment and more stable conditions for the development of biotechnology in Poland and the European Union.

- Representation of the biotechnology sector's interests in legislative processes and regulatory consultations – at both national and European levels.
- Building the image of biotechnology as a modern, diverse, and strategically important sector for the economy.
- Co-creating biotechnology development strategies in Poland in cooperation with public administration and the scientific community.
- Advocating for dedicated funding programs and financing pathways for biotechnology, taking into account the different segments of the industry.

- Continuous communication of the successes and challenges of member companies to key institutions, including:
 - the Ministry of Development and Technology,
 - PARP,
 - the Ministry of Health,
 - NCBR,
 - the Ministry of Agriculture,
 - PFR,
 - the Ministry of Funds and Regional Policy,
 - ABM,
 - the Agency for Health Technology Assessment and Tariff System (AOTMiT).
- Active participation in shaping the regulatory environment so that legislation keeps pace with innovation rather than hindering it.

INTERVENTIONS IN INDIVIDUAL MEMBER CASES

- Support in tax-related matters, including:
 - VAT issues,
 - proceedings before WIS and KAS.
- Interventions through the Ombudsman for Small and Medium-Sized Enterprises.
- Support in interactions with Agency for Health Technology Assessment and Tariff System, including:
 - obtaining official positions and opinions,
 - substantive support in assessment processes.
- Actions at the parliamentary level, including:
 - parliamentary interpellations,
 - oversight procedures and formal inquiries on matters important to the industry.
- Interventions at the level of regional and local authorities.
- Representation of member companies in legislative processes.
- Ongoing consultations and advisory support on issues critical to business operations.

AGRARIUS

**Baker
McKenzie.**



KRK Legal & Regulatory

 MediSensonic

nanQGROUP



BRP BIORESEARCH PHARMA

BIOTON

 康龙化成
PHARMARON

 Pharm**bio**test
Poland

POLSERVICE
KANCELARIA RZECZNIKÓW
PATENTOWYCH

BOOST
HIGH

 **BRILLAW**
BY MIKULSKI & PARTNERS

CRIDO

 **QIAGEN**
BLIRT is officially renaming to QIAGEN Gdańsk!

 **RTTECHNIK**

 1816
SGGW
Wydział Biologii
i Biotechnologii

diCELLa

 **EndoLink**

FGGH IP
WARSZAWA • KRAKÓW • GDAŃSK

 **Łukasiewicz**
PORT Polski Ośrodek
Rozwoju Technologii

syvento | BIO
TECH

 **UNIwersytet
JAGIELLOŃSKI
W KRAKOWIE**

FiLeCio

foodtech.ac

**POLONIUM
FOUNDATION**



 **UNIwersytet MEDYCZNY**
IM. PIASTÓW ŚLĄSKICH WE WROCŁAWIU

**WAR WSP
DYN ŒLN
SKI+ ICY.**

 **HELPI**
OPTICS

 **IMol**

 **nencki institute**
of experimental biology

WPD 
Pharmaceuticals

**You
Nick**
Mint
Venture
capital.

 **INSTYTUT BIOTECHNOLOGII
PRZEMYSŁU ROLNO-SPOŻYWCZEGO**
im. prof. Wacława Dąbrowskiego

IMD  **Instytut Medycyny Doświadczalnej i Klinicznej**
im. Mirosława Mossakowskiego
Polskiej Akademii Nauk

 **ITS**
SCIENCE

AGRARIUS

address

ORGANIKA-AGRARIUS Sp. z o. o.
Pratkowce 177/1, 37-700 Przemyśl

contact

tel.: +48 566 566 005
e-mail: biuro@itssscience.pl

www

www.agrarius.eu

AGRARIUS

AGRARIUS

is a Polish manufacturer of innovative and safe solutions for agriculture, horticulture, orchard production, and forestry. For two decades, it has been supporting agricultural producers in building modern, high-quality, and sustainable agriculture. The foundation of the company's operations is the creation of products based on effective, modern, and natural technologies that truly support plants during periods of intensive growth and environmental stress. This allows farmers to achieve higher and better-quality yields that meet the growing demands of the market and consumers.

The AGRARIUS portfolio includes growth stimulants and plant resistance inducers, microbiological preparations, foliar fertilizers, solutions supporting soil regeneration, and specialized products for fruit growing and forestry. All products are based on the highest quality ingredients and many years of research and development experience. Their effectiveness has been confirmed both in studies conducted by renowned scientific institutions and research institutes, as well as in field practice on the plantations of farmers, fruit growers, and vegetable producers. The strength of AGRARIUS lies in its specialized team of experts and a knowledge base composed of specialists and PhDs in agriculture, agricultural chemistry, microbiology, biotechnology, and modern crop production. The company does not limit its activities solely to the sale of products. A key element of AGRARIUS's philosophy is educating agricultural producers and young people who see their future in agriculture, providing practical knowledge on sustainable biological farming practices, soil regeneration, improving crop quality and food security, and modern methods of supporting plant immunity.

AGRARIUS remains close to farmers through active participation in trade fairs, field days, educational events, and field meetings organized throughout Poland. The company continuously collaborates with agricultural producers, offering expert advice based on field experience, technology, and research results. Direct contact with agricultural practice allows not only for the effective implementation of modern solutions but also for a better understanding of the real challenges facing modern agriculture.

AGRARIUS



Training and research are also important areas of AGRARIUS's activities. The company organizes numerous training courses for farmers, advisors, and business partners throughout the country and actively participates in scientific conferences and industry events related to plant cultivation, biotechnology, and agriculture in its broadest sense. Continuous development of expertise, collaboration with the scientific community, and the constant search for new technologies allow AGRARIUS to build its position as a partner and provide expert support to farmers in times of growing climatic, environmental, and economic challenges. Operating in accordance with the principle of "In Harmony with Nature," AGRARIUS consistently develops solutions that support sustainable agriculture, food security, and the restoration of environmental biological balance. The company combines science, technology, and practice, creating solutions that meet the needs of modern agriculture of the future.



Biomed Warszawa

address

30/34 Chelmska St.
00-725 Warsaw, Poland

contact

+48 22 841 06 06
biuro@biomed.com.pl

WWW

biomed.com.pl



BIOMED

BIOMED: PHARMACEUTICAL SECURITY & INNOVATION

BIOMED is one of Europe's specialized manufacturers of biological pharmaceuticals, antitoxins and serum-derived medicinal products. As a state-owned enterprise, BIOMED contributes to Poland's pharmaceutical security through the production of specialized biological medicinal products.

The company specializes in small-volume, high-complexity biological pharmaceutical production, a rare capability increasingly recognized as essential for healthcare preparedness and pharmaceutical supply security. BIOMED manufactures complete pharmaceutical products from raw active pharmaceutical ingredients through final formulation, ensuring complete control of critical, life-saving medicines.

PRODUCT PORTFOLIO: LIFE-SAVING MEDICINES

- Viper venom antitoxin (Antytoksyna jadu żmij)

Emergency treatment for European viper bites (*Vipera berus*).

BIOMED is the only manufacturer of viper antitoxin in Poland and one of the few manufacturers in Europe.

- Botulinum Antitoxin ABE (Antytoksyna Botulinowa ABE)

Emergency treatment for botulism poisoning caused by botulinum toxin types A, B, and E.

BIOMED is one of the few global producers of this key antitoxin.

Additional Pharmaceutical Products:

- Protamine Sulfate 1% - Critical care medicine used for heparin reversal.
- BIOSTREPTA - Enzyme-based preparations (suppositories and tablets)
- Active Pharmaceutical Ingredients - Complete in-house API production

MANUFACTURING EXCELLENCE

- Rapid response capability for public health emergencies
- Flexible production enabling precise volume matching to demand
- Advanced quality control with detailed testing of every series
- In-house API production ensuring supply chain independence
- Production located in Europe supports more efficient distribution across the region
- Platform for development and implementation of specialized biotechnological processes

REGULATORY STATUS & CERTIFICATION

GMP Certification: GMP-certified manufacturing for human medicinal products, veterinary medicinal products, investigational medicinal products and active pharmaceutical ingredients.

COMPETITIVE ADVANTAGES

- One of the few global producers of Botulinum antitoxin ABE
- One of the few European producers of Viper venom antitoxin
- Decades of experience in maintaining marketing authorizations for biological medicinal products.
- Full vertical integration from API to finished product
- State ownership supports long-term strategic continuity of operations
- Highly qualified staff, including PhD-level scientific personnel
- Experience in process development and technology optimization
- Building partnerships with universities and research institutions

MANUFACTURING FACILITY & INFRASTRUCTURE

- Production Areas:
- Aseptic/Sterile manufacturing
- Non-sterile production
- API purification and concentration laboratory
- Quality control and testing laboratories
- GMP-compliant warehouse and storage
- Specialized facilities for serum-derived and biological medicinal products

BIOMED is seeking partners in:

- biological pharmaceutical manufacturing,
- technology transfer,
- contract manufacturing (CDMO),
- strategic stockpiling programs,
- clinical development,
- research collaborations,
- EU-funded projects,
- international distribution,
- strategic partnerships in biological emergency countermeasures.



BIOMED specializes in rare, technologically demanding biological medicines that are maintained in production despite low sales volumes precisely because of their life-saving, emergency-use importance. With over 85 years of uninterrupted expertise, BIOMED stands as a strategic pillar of European pharmaceutical security – ensuring that critical antitoxins remain available when no commercial alternative would.

Bionexen Sp. z o.o.

address

ul. Komfortowa 1/1
02-995 Warsaw, Poland

contact

tel: +48 510 899 020
e-mail: kontakt@bionexen.com

www

www.bionexen.com



BIONEXEN:

ADVANCED SINGLE-USE SYSTEMS & BIOTECH ENGINEERING

Bionexen is a specialized Polish biotechnology provider dedicated to delivering high-quality equipment, expertise, and custom-engineered solutions for laboratories, research facilities, and the pharmaceutical and biotechnology manufacturing sectors. The company bridges advanced manufacturing technology with deep industry know-how, empowering bioprocess development and enabling seamless scale-up from laboratory R&D to full industrial production.

CORE PORTFOLIO & CAPABILITIES

- **Single-Use Systems (SUS):** Custom design and supply of single-use assembly sets engineered specifically for biopharmaceutical processes, laboratory workflows, and sterile fluid management.
- **2D & 3D Single-Use Bags:** High-purity, reliable bioprocess 2D and 3D bags designed for safe storage, mixing, and transfer of biological liquids and sensitive biopharmaceutical media.
- **Ready-to-Use Solutions:** Standardized and tailored ready-to-use liquid solutions and bioprocessing reagents optimized for cleanroom and biomanufacturing applications.
- **Facility Engineering & Design:** End-to-end conceptual design and execution of specialized laboratory and biomanufacturing areas, fully aligned with stringent biotech and pharmaceutical industry standards.

COMPREHENSIVE CONSULTING & IMPLEMENTATION

Bionexen goes beyond product delivery by offering professional support and consulting throughout the implementation lifecycle of Single-Use Systems. The company supports clients in optimizing process parameters, improving bioprocess efficiency, reducing cross-contamination risks, and implementing scalable, flexible production infrastructure.

By combining technical expertise with a flexible, client-focused approach, Bionexen serves as a trusted technological partner for organizations seeking modern, efficient, and compliant bioprocess architecture.

BioResearch Pharma

address

ul. Zygmunt Glogera 2/11
02-051 Warszawa

contact

office@bioresearchpharma.com

www

www.bioresearchpharma.com



BIORESEARCH PHARMA:

INNOVATIVE TOPICAL DERMATOLOGY THERAPIES

BioResearch Pharma S.A. is a clinical-stage Polish clinical biotech company focused on developing novel, patented topical treatments for dermatological conditions with high unmet medical needs. The company leverages drug repositioning—using established, well-characterized active pharmaceutical ingredients in new therapeutic indications and advanced topical formulations—to deliver safe, effective, and lower-risk therapies to global markets.

CORE R&D PIPELINE & ASSETS

- **BRP-011 (Androgenetic Alopecia):** A proprietary topical formulation targeting hair loss. It aims to offer a novel mechanism of action with improved safety and efficacy profiles compared to standard treatments, restoring hair growth and improving patient quality of life.
- **BRP-007 (Plaque Psoriasis):** A novel topical drug candidate developed for mild-to-moderate plaque psoriasis—a condition affecting over 90% of psoriasis patients. BRP-007 is designed to overcome the key limitations, side effects, and application challenges associated with conventional topical therapies.



BUSINESS MODEL & VALUE CREATION

BioResearch Pharma operates on a de-risked, high-efficiency development strategy:

- **Accelerated Time-to-Market:** By utilizing repositioned, proven active compounds, the company significantly reduces development timelines, clinical failure risks, and overall R&D costs compared to traditional novel-molecule drug discovery.
- **Advanced Formulation & Delivery:** BRP develops tailored, patient-friendly topical formulations (e.g., creams, solutions, lipid nanocarriers) to maximize targeted skin penetration while minimizing systemic exposure with conventional topical therapies.
- **Commercialization & Strategic Partnerships:** The company advances its pipeline candidates through rigorous preclinical and Phase I/II clinical trials, aiming to partner with or license out drug candidates to international pharmaceutical partners for global commercial expansion.

BIOTON S.A.

address

ul. Starościńska 5, 02-516
Warszawa, Poland

contact

bioinfo@bioton.com

WWW

www.bioton.com



BIOTON S.A.

IS A DYNAMIC EUROPEAN BIOTECH COMPANY

listed on the Warsaw Stock Exchange, with over 25 years of expertise in providing patients with essential diabetes care solutions. As a trusted global healthcare partner, BIOTON is 1 of only 8 worldwide producers of Recombinant Human Insulin (RHI) and the sole producer in Poland managing the complete manufacturing cycle- from biosynthesis of the active substance to the finished drug product.

With a 40%+ volume market share in recombinant human insulin in Poland, BIOTON secures the treatment of approximately 100,000 Polish patients daily and expands its international presence across 35+ countries. The company operates a state-of-the-art manufacturing facility in Poland employing around 400 dedicated specialists.

KEY COMPANY HIGHLIGHTS

- **Full-Cycle Biotech Production:** Biosynthesis, purification, formulation, fill & finish.
- **Proven Regulatory Compliance:** Confirmed EU GMP certificates, positive audits by Big Pharma and international Health Regulatory Agencies (e.g., ANVISA).
- **Dedicated MS&T & R&D Teams:** In-house process development and scale-down modeling

GLOBAL REACH & CAPACITY

- **RHI API Active Substance:** 1,500 kg/ year current capacity (DS expansion up to +800 kg).
- **Finished Dosage Forms:** 95 million cartridges and 10 million vials per year.
- **Global Footprint:** Present across 35+ markets in Europe, Asia, Latin America, and Africa.

PRODUCT PORTFOLIO

BIOTON provides integrated, high-quality diabetes management solutions designed to meet evolving patient needs:

- **Recombinant Human Insulin (GENSULIN®):** High-purity European human insulin available in vials and cartridges (GENSULIN® R short-acting, GENSULIN® N intermediate-acting, GENSULIN® M30 bi-phasic). Features high purity, 36-month long-term stability, and proven in-use stability up to 30°C and 75% humidity.
- **Delivery Devices (GensuPen®2):** Advanced, automatic, low-force insulin injection pens providing precise administration (up to 60 IU, 1 IU increments), constant injection speed, and audible/visible end-of-dose signaling.
- **Oral Antidiabetic Drugs & Supportive Therapies:** Portfolio including Avamina (Metformin), Pioglitazone Bioton, Sitagliptin Bioton, Combodiab, and Alfalipon Bioton.
- **Next-Generation Pipeline:** Development of insulin analogues (Lispro, Glargine, Aspart), GLP-1 receptor

Contract Manufacturing & CDMO/CMO Services

Leveraging deep biotechnology expertise and high-volume infrastructure, BIOTON offers comprehensive contract services from gene to commercial drug product:

SERVICE AREA

CAPABILITIES & INFRASTRUCTURE

Process Development & Scale-Down Lab

Full biotech production cycle (USP, Harvest, Refolding, DSP). Bioreactor testing from 1L, 5L, and 75L up to commercial-scale 1,500L and 10,000L units.

DP Formulation Platform

High-throughput liquid formulation screening (48 variants in one DoE experiment), fully automated robotic platforms, and real-time kinetic analysis.

EU GMP QA/QC Services

Chemical, microbiological, and bioengineering laboratories; full stability testing (long-term, accelerated, photostability); analytical method development, validation, and transfer; batch release of drug substances, finished dosage forms, and medical devices to EU markets.

Commitment to Sustainability (ESG)

BIOTON actively integrates environmental, social, and governance principles across all operations. The company is transitioning to renewable energy sources, continuously boosting energy efficiency, and maintaining industry-leading waste recycling standards (achieving a 98.5% waste recycling rate). High ethical standards, operational transparency, and continuous employee training form the cornerstone of BIOTON's corporate policy.

BoostHigh Sp. z o.o.

address

ul. Bydgoskich Przemysłowców 6
85-862 Bydgoszcz, Poland

contact

tel: +48 665 002 628
e-mail: office@boosthigh.com

WWW

www.boosthigh.com



BOOSTHIGH:

ADVANCED SOFTWARE & DIGITAL TECHNOLOGY PARTNER FOR LIFE SCIENCES

BoostHigh is an innovative custom software development and technology partner supporting enterprises, research organizations, and high-tech industries, including the biotechnology, medtech, and pharmaceutical sectors. Combining deep engineering expertise with agile project management, the company delivers tailored digital solutions that accelerate research, optimize automated workflows, and empower digital transformation in regulated environments.



CORE SERVICES & TECHNICAL EXPERTISE

- **Tax & Legal Advisory:** Comprehensive tax planning, structuring, and compliance, alongside specialized legal support covering corporate law, mergers and acquisitions (M&A), intellectual property (IP), and dispute resolution.
- **R&D Tax Incentives & Innovation Support:** Expert assistance in maximizing financial returns from research and development activities through dedicated tax reliefs (such as the Polish R&D tax credit and IP Box).
- **EU Grants & Public Funding:** Strategic identification, acquisition, and settlement of non-dilutive public financing, including national and European grants (e.g., FENG, Horizon Europe, LIFE) tailored for biotech laboratories, clinical trials, and commercial scaling.
- **Investment & Business Consulting:** Support in structuring investment projects, public aid utilization (including the Polish Investment Zone), and financial modeling for high-growth technological enterprises.



STRATEGIC PARTNER FOR INNOVATION

CRIDO stands out through its unique ability to combine financial, legal, and strategic competencies under one roof. By working closely with biotech start-ups, scaling enterprises, and international corporations, CRIDO helps clients minimize regulatory risks, leverage state and EU support mechanisms, and build a solid foundation for long-term commercial success in the life sciences sector. v

CRIDO

address

Towarowa 28 (Generation Park Z)
00-839 Warsaw, Poland

contact

tel: +48 22 324 59 00
e-mail: crido@crido.pl

WWW

www.crido.pl

CRIDO

CRIDO:

COMPREHENSIVE BUSINESS, TAX, LEGAL & GRANT ADVISORY FOR LIFE SCIENCES

CRIDO is a leading multi-disciplinary advisory firm in Poland, supporting businesses across dynamic sectors—including biotechnology, pharmaceuticals, medtech, and life sciences—in navigating complex legal, regulatory, and financial landscapes. Combining deep industry insight with comprehensive technical expertise, CRIDO delivers integrated advisory services designed to accelerate corporate growth, optimize R&D investments, and secure funding for innovative projects.



CORE SERVICES & EXPERTISE

- **Custom Web & Software Development:** Designing and building robust, scalable web platforms and enterprise applications tailored to specific business and scientific operations.
- **C++ & High-Performance Computing:** Developing high-efficiency software systems requiring advanced computational power, real-time data processing, and precise hardware integration.
- **Internet of Things (IoT) Solutions:** Connecting laboratory instruments, hardware devices, and industrial machinery into unified monitoring and management ecosystems.
- **Interactive & Immersive Technologies:** Delivering modern digital experiences, including specialized software support for trade fair exhibitions, interactive presentations, and advanced product visualizations.



COLLABORATION & BUSINESS APPROACH

BoostHigh operates on a philosophy of close technological partnership, guiding clients from initial product analysis and architecture design through full implementation and long-term maintenance. By bridging advanced software engineering with practical industry needs, BoostHigh helps life science and technology companies scale their digital infrastructure, improve operational efficiency, and successfully bring modern tech-driven products to market.

diCella Sp. z o.o.

address

Podole 60 Street
30-394 Krakow, Poland

contact

e-mail: contact@dicella.com

WWW

www.dicella.com



DICELLA:

INTEGRATED ECLINICAL PLATFORM FOR MODERN CLINICAL TRIALS

diCELLa Sp. z o.o. provides advanced, integrated software designed to simplify, accelerate, and streamline the execution of complex clinical trials. By combining study setup, data capture, trial operations, documentation, and patient engagement into a single unified platform, diCELLa helps sponsors, CROs, and clinical research teams launch studies faster, maintain full operational visibility, and meet strict regulatory compliance standards.

CORE PLATFORM MODULES & CAPABILITIES

- **eCRF & Clinical Data Capture:** Flexible electronic case report form configuration with clean startup logic, review cycles, and fully traceable data collection.
- **eTMF (Trial Master File):** Centralized, inspection-aware document management kept continuously aligned across sponsors, CROs, and trial sites.
- **CTMS & Trial Operations:** Comprehensive trial management tools to coordinate timelines, site activities, and operational milestones while eliminating blind spots.
- **IWRS & Randomization:** Integrated randomization and supply workflow management designed directly within the core operating system.
- **Patient Diary & Engagement:** Digital tools capturing patient-reported outcomes (ePRO/eCOA) and direct study interactions seamlessly connected to central study data.
- **AI Engine & Rapid Setup:** AI-assisted configuration tools that analyze protocols to deliver a working study demo in under 5 days and achieve a recruitment-ready setup in approximately 3 weeks.

DATA INTEGRITY & COMPLIANCE MINDSET

diCELLa features a unique, patented technology approach (EP3945704A1) that utilizes blockchain-based security to ensure maximum data integrity, tamper resistance, and full audit trail control for clinical and laboratory records. Built with a strict regulatory focus, the platform adheres to 21 CFR Part 11, GCP guidelines, and ISO-based processes, giving clinical teams complete confidence in their operational evidence.

ENDOLINK S.A.

address

ul. Piotrkowska 46/8U,
90-265 Łódź

contact

biuro@endolink.pl

WWW

www.endolink.pl



EndoLink Group

to dom innowacji medycznych z siedzibą w Łodzi, łączący projekty badawczo-rozwojowe, komercyjne marki i instrumenty finansowania innowacji zdrowotnych. Fundamentem grupy jest chirurgia naczyniowa – to z niej wyrasta DNA EndoLink Group i to ona pozostaje kręgosłupem działalności, wokół którego budujemy kolejne obszary kompetencji. Przez ponad 15 lat działalności na rynku medycznym zbudowaliśmy model wyróżniający nas spośród typowych firm medtech: jeden zespół prowadzi projekt od koncepcji klinicznej, przez walidację i certyfikację, aż po wdrożenie rynkowe i finansowanie ekspansji.

Chirurgia naczyniowa – core biznes grupy

Punktem wyjścia i trwałym fundamentem EndoLink Group jest zaawansowana chirurgia naczyniowa. Oferujemy sprawdzone rozwiązania wykorzystywane podczas endowaskularnych procedur chirurgicznych – stentgrafty Lombard Medical oraz produkty towarzyszące, stosowane na salach operacyjnych wiodących ośrodków naczyniowych w Polsce. To doświadczenie zdobyte na sali operacyjnej stało się punktem wyjścia dla projektów R&D rozwijanych dziś w ramach grupy.

R&D — INNOWACJE W TOKU

W portfelu R&D EndoLink Group znajdują się cztery autorskie rozwiązania z obszarów chirurgii naczyniowej, urologii i medycyny ratunkowej.

Infinity Flow / CircuLife to dwa powiązane projekty z obszaru technologii naczyniowych. Infinity Flow wspomaga przepływ krwi podczas chirurgii naczyniowej poprzez shunting tętnicy szyjnej, redukując obciążenie zespołu operacyjnego przy zachowaniu perfuzji mózgowej. CircuLife to technologia z myślą o medycynie pola walki i ratownictwie medycznym, zwiększająca szanse na zachowanie kończyny u ciężko rannych pacjentów – w warunkach wojсковych i przy wypadkach drogowych czy urazach masowych. CircuLife jest finalistą programu InCredibles Sebastiana Kulczyka.

Perun / StentPoint to system do endowaskularnego leczenia aorty, ze szczególnym zastosowaniem w jej rozwarstwieniach, odpowiadający na zapotrzebowanie na precyzyjne narzędzia skracające czas i złożoność procedury.

UROstop to urządzenie zewnętrzne dedykowane mężczyznom z łagodnym lub umiarkowanym wysiłkowym nietrzymaniem moczu, minimalizujące potrzebę interwencji chirurgicznej.

Vascular Digital Twin to projekt z obszaru cyfrowej medycyny tworzący wirtualne modele układu naczyniowego pacjenta na potrzeby planowania zabiegów endowaskularnych i wsparcia decyzji klinicznych.

MARKI KOMERCYJNE

Równoległe z projektami R&D EndoLink Group rozwija marki adresowane do różnych segmentów rynku ochrony zdrowia.

LimbXpert skupia kompleksową ofertę z zakresu rehabilitacji i zaopatrzenia ortopedycznego. EndoLink Group jest wyłącznym polskim dystrybutorem systemów FREE Walk oraz NimBo – egzoskieletów i systemów robotycznych wspomagających rehabilitację kończyn górnych i dolnych, przeznaczonych dla pacjentów po urazach oraz osób starszych wymagających wsparcia w codziennym funkcjonowaniu.

Orvicta to marka suplementacji funkcjonalnej, oferująca produkty wspierające zdrowie poznawcze i ogólny dobrostan pacjenta.

Meravita Care to marka kosmetyczna oferująca produkty z obszaru pielęgnacji skóry i profilaktyki estetycznej, łącząca nowoczesne składniki aktywne z podejściem prozdrowotnym.

FINANSOWANIE INNOWACJI

Model EndoLink Group obejmuje własne instrumenty wsparcia finansowego. MediFactor to usługa faktoringu medycznego umożliwiająca podmiotom z sektora ochrony zdrowia utrzymanie płynności finansowej. EndoFund to platforma inwestycyjna skoncentrowana na projektach z obszaru life sciences.

OBECNOŚĆ MIĘDZYNARODOWA

EndoLink Group aktywnie uczestniczy w europejskim ekosystemie innowacji medycznych, obecna na wiodących kongresach endowaskularnych i rehabilitacyjnych w Europie, budując partnerstwa z ośrodkami klinicznymi i podmiotami branżowymi.



FGGH IP Patent and Law Firm

address

Q22 Al. Jana Pawła 22
00-133 Warsaw, Poland

contact

contact@fgghip.com

www

www.fgghip.com

FGGH IP

FGGH IP

is an intellectual property patent and law firm with offices in Warsaw, Kraków, and Gdańsk, dedicated to delivering strategic, business focused solutions for the protection and management of intellectual assets.

The FGGH IP team consists of European and national patent attorneys, attorneys at law, and industrial property valuation specialists. FGGH IP provides comprehensive services covering patents, trademarks, industrial designs, copyright, licensing, portfolio management, and enforcement, as well as representation before the Polish Patent Office, EUIPO, EPO, and the Unified Patent Court.

Clients value the team members' expertise in intellectual property matters. They have been actively supporting clients in obtaining and maintaining protection, and enforcing industrial property rights, for over 25 years.

A multidisciplinary team combines legal precision with commercial insight, ensuring solutions that are strategic, transparent, and client oriented. Going beyond the standard range of services, FGGH IP aims to offer the clients something more with a CONCIERGE IP service, which provides integrated support in the management of intellectual property rights: providing expert advice, support and assistance in services offered by patent attorneys, attorneys at law, tax advisors, intellectual property valuation specialists, and mediators.

Over the past years, FGGH IP has been recognized in numerous prestigious international rankings dedicated to intellectual property, including: IAM Patent 1000 – The World's Leading Patent Professionals, Managing IP – IP Stars, The Legal 500 and Lexology Index.

At FGGH IP, we believe that valuable ideas grow through dialogue, and we welcome every opportunity to share our expertise and learn from others.

TEAM:

Iwona Płodzich-Hennig patent attorney

She is a patent attorney with 23 years of work experience, during which she gained rich and diverse professional experience, working for 12 years in pharmaceutical company and the next 11 years as a patent attorney in the patent law firm. She is a biotechnologist by education, dealing with LifeScience cases

Piotr Godlewski national and European qualified patent attorney, UPC representative

He is a national and European patent attorney with more than hundreds of patent applications before the European Patent Office the Polish Patent Office. He is a biotechnologist by education, and for the past 18 years his daily practice has been operating in the broadly defined area of Life Science.

Helena Gajek attorney at law, trademark and patent attorney

She is a patent attorney with 18 years of work experience, specialized in issues related to the protection of intellectual property rights. As an experienced lawyer, she has repeatedly litigated cases involving patents, trademarks and industrial designs, appearing before civil and administrative courts, Polish Patent Office, EUIPO and WIPO.

Alicja Kicińska-Fujawa attorney at law, trademark and patent attorney, European patent attorney, UPC representative

With her support, clients from various industries, ranging from FMCG to automotive, fuel, tools and devices, roofing and life sciences, have built and enriched their trademark portfolios (more than 2,000 trademark applications) or industrial designs (more than 200 registrations). She has extensive experience – for the past 30 years advising in IP.

Jacek Stachowski patent attorney, IP valuation expert

The portfolio of cases he has handled also includes international PCT applications and national phase proceedings in designated countries. In addition, he is experienced in conducting patent searches, (including FTO), opinions and documentation accompanying grant applications. He is also specialized in business valuation issues (patents monetization).

FiLeClo Sp. z o.o.

address

Al. Piłsudskiego 141
92-318 Łódź, Poland

contact

e-mail: poczt@fileclo.pl

www

www.fileclo.pl



FILECLO:

ADVANCING TARGETED ONCOLOGY & NOVEL CANCER THERAPEUTICS

FiLeClo Sp. z o.o. is a Polish biopharmaceutical enterprise focused on the development and commercialization of innovative, high-tech R&D projects in targeted oncology. Named after the rare „five-leaf clover” symbol of extraordinary potential, the company leverages cutting-edge biomedical research to develop next-generation therapeutics designed to overcome the key limitations of conventional chemotherapy.

CORE R&D FOCUS & SCIENTIFIC PIPELINE

- **Salinomycin-Based Targeted Therapies:** Development and optimization of proprietary salinomycin derivatives and drug candidates (such as FLC-436) targeting cancer stem cells (CSCs), which are responsible for tumor recurrence and resistance to standard therapies.
- **Low-Toxicity Cytostatics:** Research into targeted therapeutic agents capable of delivering high cytotoxic efficacy against aggressive and currently incurable cancers while minimizing systemic side effects.
- **Preclinical Development & Testing:** Conducting comprehensive in vitro and in vivo preclinical evaluations, pharmacological profiling, and bioanalytical assays to advance drug candidates toward clinical development.

VISION & STRATEGIC OBJECTIVES

FiLeClo operates at the intersection of academic research and commercial biotechnology. By combining rigorous scientific methodologies with strategic R&D management, FiLeClo aims to bring breakthrough oncological solutions to the global biopharmaceutical pipeline, focusing on targeted cancer treatments with improved therapeutic windows and enhanced patient safety.

Helpi Optics Sp. z o.o.

address

ul. Okulickiego 5F
05-500 Piaseczno

contact

+48 571 356 575
kontakt@helpi-optics.pl

www

helpi-optics.pl



Helpi Optics

SP. Z O.O.

is a modern technology company operating at the intersection of life science and material science, specializing in the provision of advanced research and diagnostic equipment.

As an authorized distributor of Olympus (Evident Scientific) microscopy in Poland, we combine global technologies with local support for laboratories, hospitals, universities, and industry.



OUR PORTFOLIO INCLUDES, AMONG OTHERS

- optical and digital microscopes,
- electron microscopes (SEM) – the latest addition to our offer,
- imaging and analysis systems for biological and material sciences,
- histopathological preparation equipment,
- 3D bioprinters,
- atomic force microscopes (AFM) and systems for bioelectric cell research.

We provide comprehensive support at every stage of cooperation – from technology selection and demonstration, through sales and implementation, to service and application development.

Thanks to our team's experience and close cooperation with manufacturers, we help clients accelerate research, increase diagnostic precision, and implement modern solutions in practice.

Helpi Optics is a technology partner for institutions that want to see more – faster and more accurately.



Nencki Institute of Experimental Biology, Polish Academy of Sciences

address

3 Pasteur Street,
02-093 Warszawa

contact

business@nencki.edu.pl

www

nencki.edu.pl



Nencki Institute


OF EXPERIMENTAL BIOLOGY OF THE POLISH ACADEMY OF SCIENCES

is a publicly funded life science and biomedical research institute with over 100 years of scientific excellence. Its activities are centred on research, innovation, and education, with a strong focus on developing new therapies, diagnostics, and technologies addressing cancer, diabetes, neurodegenerative and neurological disorders, and other diseases of modern civilization.

CORE FACILITIES

The Institute operates eight state-of-the-art core facilities providing comprehensive research services for academia and industry.

Laboratory of Behavioral Methods provides high-quality behavioural screening and testing services for academia and industry, focusing on animal models in biomedical research. The laboratory offers end-to-end support, from experimental design and equipment development to study execution, statistical analysis, and manuscript preparation.




Laboratory of Brain Imaging provides state-of-the-art, non-invasive neuroimaging for human brain research, including fMRI, sMRI, MRS, EEG, and TMS. The laboratory also offers complementary equipment and software supporting a wide range of experimental paradigms.

Laboratory of Cytometry provides multicolour and full-spectrum flow cytometry and cell sorting, supporting experimental design, data acquisition, and advanced analysis. Its expertise focuses on cancer biology, cell-cell interactions, and the leukaemia microenvironment. **Laboratory of Electron Microscopy** provides comprehensive electron microscopy and histology services for academia and industry, from experimental design to qualitative and quantitative ultrastructural analysis. Its expertise includes imaging of protein complexes, cells and tissues, EDX analysis, and electron tomography.

Laboratory of Electrophysiology provides state-of-the-art electrophysiological recordings and optogenetic tools for functional analysis of synaptic transmission. The laboratory offers comprehensive support in experimental design, execution, and data analysis.

Laboratory of Imaging Tissue Structure and Function provides advanced optical and electron microscopy for structural and functional analysis of biological samples, supported by image analysis and visualization tools for quantitative data interpretation.

Laboratory of Preclinical Testing of Higher Standard performs GLP-compliant preclinical in cellulo and in vivo evaluation of novel therapeutics for cancer and neurological diseases. Services include experimental design, cytotoxicity and efficacy testing, mouse disease models (e.g. Alzheimer's), toxicology, behavioural studies and data analysis.




Laboratory of Sequencing provides library preparation, next-generation sequencing, and bioinformatic analysis of genomic, transcriptomic, and epigenomic data. The laboratory offers established workflows for whole-genome, mRNA, and single-cell sequencing, supported by expert data analysis.

BIOPIXEL NATIONAL BIOIMAGING CENTRE

Located at the Institute's Research Station campus in Mikołajki, BioPixel National Bioimaging Centre is a state-of-the-art research infrastructure equipped with next-generation microscopy, advanced in vitro and in vivo imaging systems, and extensive analytical platforms. BioPixel provides integrated services in biological imaging, sequencing, flow cytometry, electrophysiology, molecular biology, genetic engineering, peptide synthesis, metabolic and behavioural studies. Furthermore, Biopixel's Laboratory of Bioinformatics offers comprehensive analyses of omics data, physiological and behavioral signals, images and traditional biomedical data, using established and machine learning methods. It also supports ontological analyses, biological interpretation, and experimental design.

CENTRE FOR TRANSLATIONAL RESEARCH

Centre for Translational Research accelerates the translation of scientific discoveries into clinical applications, with particular emphasis on biomarkers, innovative therapies, early diagnostics, and precision medicine. The Centre integrates high-resolution electron microscopy, advanced optical imaging, and analytical and modelling platforms enhanced with artificial intelligence and machine learning, enabling bioimaging and data analysis from the molecular level to the whole organism.



Prof. Wacław Dąbrowski Institute of Agricultural and Food Biotechnology – State Research Institute (IBPRS-PIB)

address

ul. Rakowiecka 36
02-532 Warsaw, Poland

contact

tel: +48 22 56 64 200

WWW

www.ibprs.pl



IBPRS-PIB:

PIONEERING AGRICULTURAL & FOOD BIOTECHNOLOGY RESEARCH

The Prof. Wacław Dąbrowski Institute of Agricultural and Food Biotechnology – State Research Institute (IBPRS-PIB) is a leading Polish public research organization with over 70 years of expertise in industrial biotechnology, food microbiology, food processing technologies, and quality control. Operating under the supervision of the Ministry of Agriculture and Rural Development, IBPRS-PIB serves as a key bridge between scientific innovation, food safety policy, and the commercial agrifood and bio-processing sectors.

CORE CAPABILITIES & SCIENTIFIC INFRASTRUCTURE

- **Industrial Microbial Collections:** Maintaining internationally recognized collections of industrial microorganisms (IAFB culture collection), providing bio-resources and specialized starter cultures for food, feed, and fermentation industries.
- **Bioprocessing & Fermentation Technology:** R&D in enzyme technology, biomass conversion, valorization of food side-streams, organic acids, and sustainable industrial fermentation processes.
- **Food Safety, Quality & Bio-Analytics:** Accredited testing and analytical laboratories providing comprehensive physical, chemical, microbiological, and sensory analyses for food, beverages, and bio-based products.
- **Specialized Industry Departments:** Operating specialized research units covering meat and fat technology, fruit and vegetable processing, grain and bakery technology, sugar technology, fermentation, and microbiology.

INDUSTRY COLLABORATION & TECHNOLOGY TRANSFER

IBPRS-PIB actively collaborates with biotech companies, food manufacturers, and international academic networks. The Institute offers contract research, technology transfer, process optimization, expert consulting, and regulatory compliance support, helping the agrifood and bio-based industries implement sustainable, high-quality, and innovative solutions.

Mossakowski Medical Research Institute, Polish Academy of Sciences (MMRI PAS / IMDiK PAN)

address

ul. Pawinskiego 5
02-106 Warsaw, Poland

contact

tel: +48 22 608 64 69
e-mail: sekretariat@imdik.pan.pl

WWW

www.imdik.pan.pl



MMRI PAS:

ADVANCING TRANSLATIONAL MEDICINE & NEUROBIOLOGY

The Mossakowski Medical Research Institute, Polish Academy of Sciences (IMDiK PAN) is a premier, publicly funded research institution specializing in medical biology, neurosciences, and translational medicine. With a prestigious A+ rating in medical sciences, the Institute combines cutting-edge basic research with clinical applications to address critical health challenges, focusing particularly on diseases of the nervous system and modern civilization disorders.

CORE RESEARCH AREAS & SCIENTIFIC EXPERTISE

- **Neurobiology & Neurosciences:** Extensive research in neurochemistry, neurotoxicology, neuropathology, experimental neurobiology, and regenerative medicine of the nervous system.
- **Translational Medicine:** Bridging laboratory discoveries („bench-to-bedside”) to develop innovative diagnostic tools, biomarkers, and therapeutic strategies for clinical practice.
- **Medical Biology & Multi-Omics:** Advanced investigations into human disease multi-omics, molecular genetics, epigenetics, oncoimmunology, and nephrology.
- **Experimental Models & Specialized Facilities:** Maintaining high-standard SPF (Specific Pathogen Free) animal facilities, molecular diagnostics for genetically modified models, and advanced bioimaging platforms.

COLLABORATION & INDUSTRY PARTNERSHIPS

MMRI PAS actively participates in leading scientific consortia (such as Biocentrum Ochota and Bioluminescence Poland) and collaborates extensively with academic centers, hospitals, and biotechnology enterprises. The Institute offers high-level scientific expertise, contract research, and technological partnerships, driving innovation in drug discovery, diagnostics, and advanced biomedical engineering.

ITS Science

address

Poświętne 25B,
26-670 Pionki
Poland

contact

tel./fax: +48 48 612 71 65
e-mail: biuro@itsscience.pl

www

www.itsscience.pl



ITS SCIENCE

ITS Science is an experienced supplier of advanced laboratory equipment for the pharmaceutical, biotechnology, cosmetics, dietary supplements, and food (including novel food) industries. For over 20 years, the company has consistently built its position in the Polish market, offering solutions supporting quality control, production process monitoring, and the safety of regulated environments. We support laboratories in companies operating in the most demanding and regulated industries – where measurement precision and instrument reliability directly impact product quality and safety.

AS THE EXCLUSIVE AUTHORIZED

distributor of Beckman Coulter devices in Poland, ITS Science provides comprehensive systems for particle distribution and size analysis, total organic carbon (TOC) measurement in water, as well as solutions for cell count and viability analysis.

ITS Science is also a distributor of renowned global brands: Evident Scientific (Olympus microscopes dedicated to pharma and biopharmaceuticals), Pharmagraph (monitoring systems and microbiological samplers for cleanrooms), ERA Waters (certified reference and consumable materials for TOC analysis), Vienna Water Monitoring Solutions (ColiMinder analyzers for rapid microbiological water quality assessment), and Delfin Industrial Vacuums (industrial vacuum cleaners for cleanrooms, including ATEX solutions).

A KEY DISTINGUISHING FEATURE

of the company is its comprehensive, collaborative approach to the client. ITS Science provides support at every stage of cooperation – from technical advice and the selection of optimal solutions, through installation, qualification, and calibration of equipment, to after-sales service and specialized training. Its in-house applications laboratory enables the development of analytical methods, the performance of custom analyses, and the optimization of measurement processes tailored to individual customer needs.

ITS Science is more than just an equipment supplier – it is a technology partner supporting laboratories in pharmaceutical, biotechnology, cosmetics, dietary supplements, and the food and novel food sectors in achieving the highest standards of quality and analytical efficiency.

Contact us – our consultants will be happy to help you select a solution tailored to your laboratory's needs. More information about our offer, products, and news can be found on our website: www.itsscience.pl



CENTRIFUGES & ULTRACENTRIFUGES

Density Gradient Automation



www.ITSScience.pl

SALES DEPARTMENT

- **Przemysław Pestka**, Customer Advisor | Particle Size Analyzers, Centrifuges, and Ultracentrifuges tel.: +48 509 267 197 | przemyslaw.pestka@itsscience.pl
- **Tomasz Żurawski**, Customer Advisor | Particle Counters, Cleanroom Systems, Industrial Vacuum Cleaners tel.: +48 577 993 883 | tomasz.zurawski@itsscience.pl
- **Wawrzyniec Pestka**, Customer Advisor | TOC Analyzers, Cell Analyzers and Counters, Microbioreactors, Microbiological Quality Analyzers tel.: +48 501 618 819 | wawrzyniec.pestka@itsscience.pl
- **Krzysztof Borkowski**, Imaging Systems Specialist | Olympus Microscopes tel.: +48 601 273 331 | krzysztof.borkowski@itsscience.pl

TECHNICAL SUPPORT DEPARTMENT (SERVICE)

- **Emil Bajson**, Head of Technical Support tel.: +48 509 407 197 | emil.bajson@itsscience.pl

APPLICATION SUPPORT DEPARTMENT

- **Karolina Wabik**, Application Advisor tel.: +48 570 103 002 | karolina.wabik@itsscience.pl

KRK Legal & Regulatory

address

Emilii Plater 25/8, 00-688
Warsaw , Poland

contact

T. +48 22 620 63 25
biuro@krk.legal

www

www.krk.legal



KRK Legal & Regulatory

is a law firm with over 20 years of experience, specialising in work for the Life Sciences & Healthcare sector – covering pharmaceuticals, medical devices, food and feed, cosmetics, and healthcare. KRK helps CMO / CDMO companies, clients running clinical trials, manufacturers, importers and distributors of pharmaceuticals and medical devices and other regulated products, as well as healthcare companies, start-ups and medtech businesses



The firm's expertise also extends to product law and product liability, competition and consumer protection, intellectual property, new technologies, AI and machine learning, compliance, and litigation and arbitration. What sets KRK apart is its combination of precision, effectiveness, and a practical approach grounded in deep knowledge of regulated markets – helping clients navigate the complexities of both Polish and EU law. The firm and its lawyers consistently rank at the top of leading Polish and international legal directories, including Chambers Europe and Legal 500. Through long-standing partnerships with leading international law firms, KRK offers clients a global reach when navigating cross-border regulatory challenges.



Medisen sonic

address

ul. Migdałowa 4
02-796 Warszawa

contact

tel: +48 22 299 12 21

WWW

www.medisensonic.com



MEDISENSONIC:

REKTHROUGH NON-INVASIVE MEDICAL DIAGNOSTICS & TECH

MediSensonic S.A. is a Polish MedTech innovation company dedicated to designing, developing, and commercializing non-invasive diagnostic, monitoring, and therapeutic devices. Leveraging advanced technologies—including microwave technique, photonics, bio-sensors, and artificial intelligence—MediSensonic creates solutions that significantly improve patient comfort, diagnostic precision, and healthcare efficiency.



CORE TECHNOLOGIES & PRODUCT PIPELINE

- **Microwave Glucometer (GlucoWave):** A non-invasive, continuous glucose monitoring device utilizing radio frequency and microwave techniques, eliminating the need for skin puncturing and biological fluid sampling.
- **Non-Invasive Blood Pressure Monitor (SpiroSonic/BP):** An innovative continuous blood pressure monitoring system that removes the need for traditional inflatable cuffs, providing real-time data for cardiology and critical care.
- **Microwave Dental Sensor (MPOD):** A non-invasive sensor designed for quick, precise assessment of tooth pulp vitality and periodontium condition during dental examinations.
- **Cardiology & Emergency Solutions:** Advanced wearable devices and bio-sensor platforms dedicated to continuous remote monitoring of vital health parameters.



STRATEGIC ADVANTAGES & COMMERCIALIZATION

MediSensonic combines a multidisciplinary team of engineers, medical doctors, and biophysicists with strong intellectual property protection (patents across European and global markets). By developing Class II and Class III medical devices, the company works toward CE and FDA certifications, aiming to transform global markets in diabetes care, cardiology, and non-invasive health monitoring through strategic licensing and international distribution partnerships.

NanoGroup S.A.

address

36, Rakowiecka St., Warsaw,
Poland

contact

nfo@nanogroup.eu

www

www.nanogroup.eu



NanoGroup

is a diversified biotech / medtech company built around disruptive innovations in transplantation medicine. The company's mission is to build one of the most predictable and consistently profitable biotech groups in the Central and Eastern European region through targeted investments in local companies with predictable partnering potential. Operating under the principle of "safe innovations, predictable returns," NanoGroup combines scientific development with a partnership-oriented business strategy.

The company's core activities are centred on organ preservation technologies, synthetic oxygen carriers, targeted drug delivery systems, and advanced nanotechnology-based therapeutic platforms. Its flagship project, NanOX, is an integrated ecosystem designed for warm ex-vivo kidney perfusion. The system includes NanOX Recovery Box, an oxygenated perfusion device operating in a broad temperature range; NanOX 4 Kidney, an innovative perfusion fluid with oxygen-carrying capacity; and NanOX 4K Perfusion Set, a dedicated single-use perfusion kit. NanoGroup aims to improve organ qualification after prolonged warm ischemia and reduce rejection rates by enabling early-stage organ regeneration during perfusion.



NanOX has already achieved significant technological breakthroughs. NanoGroup successfully preserved a kidney ex vivo for 147 hours while maintaining organ in good condition, exceeding time achieved by currently market standards as well as literature results. The company also completed a successful autotransplantation study in which a pig kidney underwent 12 hours of ex-vivo perfusion following 30 minutes warm ischemia and was subsequently retransplanted as the only kidney. The experiment, which is a gold standard for a transplant study, was a full success. NanOX Recovery Box have initiated CE certification procedure with TÜV NORD Polska, marking an important milestone toward commercialization as a Class IIb medical device.

Beyond transplantation technologies, NanoGroup is developing therapeutic and biomedical platforms, including synthetic blood substitutes, cytokine bioadsorbers, polysaccharide nanoparticle platforms, dextran nanoparticle conjugates and aptamers for both human and veterinary applications. The company recently made an indirect investment in Auxilius Pharma, company focused on Value-Added Medication. Auxilius Pharma is progressing through Phase 1b clinical trials with its flagship AUX-001 nicorandil reformulation, intended for US commercialization under the FDA 505(b)(2) regulatory pathway.



NanoGroup's strategic differentiators lie in its combination of advanced nanotechnology expertise, translational medical innovation, and commercialization-focused development strategy. The company emphasizes realistic partnering opportunities, reduced development risk profiles, and technologies with clear clinical relevance. Its management and scientific leadership combine expertise in strategic business transformation, pharmaceutical commercialization, and award-winning medical nanotechnology research.

Please contact us to take part in our journey towards the new biotech business model.

Pharmaron UK Ltd

address

West Hill Innovation Park, Hert-
ford Rd, Hoddesdon EN11 9FH

contact

dominika.pauly@pharmaron-uk.com

www

www.pharmaron.com



Pharmaron

is a premier service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. With over 25,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in delivering R&D solutions to its partners in North America, Europe, Japan, and China.

LABORATORY SERVICES

- Synthetic & Medicinal Chemistry
- Analytical Chemistry
- Computational Chemistry
- DMPK/ADME
- Biology & Pharmacology
- Safety Assessment

CHEMISTRY, MANUFACTURING & CONTROL

- Process Chemistry R&D
- Material Science
- GMP API Manufacturing
- Formulation Development
- Drug Product Manufacturing
- Commercial- scale Manufacturing



CLINICAL DEVELOPMENT

- Radiolabelled Sciences
- Clinical Bioanalysis
- Clinical Pharmacology
- End-to-end Clinical Development
- Clinical SMO

BIOLOGICS & CGT

- Discovery Biologics
- Biologics CDMO
- CGT Lab Services
- GT CDMO



Pharmbiotest Poland Sp. z o.o.

address


5 Mieszka I, Grudziądz 86-300,
Poland

contact

contact@pharmbiotest.pl

www

www.pharmbiotest.com



Pharmbiotest Poland:

INTEGRATED CLINICAL AND BIOANALYTICAL SERVICES

Pharmbiotest Poland is a GLP/GCP-certified contract research organization (CRO) specializing in comprehensive clinical research and bioanalytical services. For more than 10 years, the company has been providing full-service, end-to-end execution of Phase I clinical trials - from study synopsis and protocol development, through clinical conduct and bioanalysis, to final reporting and secure data and sample storage. An integrated site ensures efficient communication, high data quality, and optimized timelines. Our expertise also includes the research and development of generic and hybrid drugs, providing high-quality support to pharmaceutical and biotechnological companies.

KEY FACTS:

- Type: Contract Research Organization (CRO)
- Years of experience: 10+ years
- Core focus: Phase I clinical trials, bioanalytics
- Certifications: GLP, GCP
- Facilities: Clinical unit, bioanalytical laboratory



CORE CT SERVICES:

- Trial design optimization and consulting
- Medical writing and document preparation
- Regulatory submission and maintenance
- Volunteer enrolment and screening
- Clinical evaluation
- Bioanalysis & Biostatistics
- Study reporting
- Archiving of study documents and samples

CORE BIOANALYTICAL SERVICES:

- Development and validation of bioanalytical methods in line with EMA/FDA guidelines
- HPLC-MS/MS analysis for complex and high-sensitivity assays
- Analysis of biological samples from different species and matrices
- Support for chiral and derivatized compound analysis
- Full PK bioanalytical services for small molecules
- Dried blood spot (DBS/VAMS) analysis
- Drug development consulting
- Bioanalytical consulting and method optimization



AREAS OF EXPERTISE AND KEY ACHIEVEMENTS

Early Involvement from the Synopsis Stage

Early engagement of the multidisciplinary team helps reduce development risks and costs. Study synopses are evaluated by medical experts, statisticians, and the bioanalytical laboratory prior to protocol development.

Integrated Approach

All services are provided within one organization, ensuring efficient communication, streamlined timelines, and consistent data quality.

Flexible Support for Sponsors

Ability to adapt study design and operational scope to the specific needs of small and mid-size pharmaceutical and biotechnology companies.

On-Site Clinical and Bioanalytical Facilities

The clinical unit and bioanalytical laboratory are located within the same facility, eliminating the need for sample transportation and reducing logistical complexity.

Expertise in Complex Study Designs

Extensive experience in studies involving complex formulations and advanced designs, including full-replicate, two-stage study models, etc.

Proven Experience in Numbers

Over 35 completed Phase I clinical trials and more than 40 generic and hybrid drugs developed.

Therapeutic Drug Monitoring (TDM) Support

Experience in therapeutic drug monitoring, including dry blood spot (DBS) method validation and bioanalysis, as well as conventional blood sample analysis conducted in-house.

Regulatory and Quality Compliance

Strong quality management system with experience in sponsor and regulatory audits, ensuring compliance with GLP and GCP requirements.

COLLABORATION & CLIENTS

The company cooperates with pharmaceutical, R&D, and biotechnology companies from Europe and other international markets, delivering clinical studies in accordance with EMA and FDA regulatory requirements.

Polservice sp. z o.o.

address

8 Bobrowiecka St, 00-728 Warsaw,
Poland

contact

ip@polservice.com.pl

WWW

www.polservice.com.pl

POLSERVICE
KANCELARIA RZECZNIKÓW
PATENTOWYCH

POLSERVICE:

PATENT AND TRADEMARK ATTORNEYS OFFICE

Operating in the market since 1964, POLSERVICE Patent and Trademark Attorneys Office is a leading intellectual property firm in Poland and Central Europe. With decades of experience, the firm delivers comprehensive IP services to clients across diverse industries and technology sectors at both national and EU/EPO levels. Long-standing collaboration with renowned patent and law firms across Europe, the United States, Canada, Central and South America, Africa, Asia, and Australia places POLSERVICE in a strong position to provide robust legal protection for clients worldwide.

This multidisciplinary firm brings together European and Polish patent and trademark attorneys, attorneys-at-law, and advocates. POLSERVICE is organized into four specialized teams:

- Patent Team I, focusing on inventions and utility models in mechanics, mechatronics, civil and environmental engineering, materials and chemical engineering, and construction.
- Patent Team II, specializing in chemistry, biotechnology, pharmacy, electronics, IT, and new plant varieties.
- Trademark and Legal Team, handling trademarks, designs, trade names, geographical indications, domain names, unfair competition, anti-piracy and anti-counterfeiting efforts, as well as litigation, legal opinions, agreements, and broader legal aspects of IP.
- Annuities Team, managing patent annuity payments, patent translations, and general IP protection queries.

The firm serves a diverse client base, including multinational corporations, SMEs, start-ups, research centers, and universities, and offers a one-stop-shop experience across a full range of IP services, from searches and prosecution to renewals, recordals, licensing, and enforcement (litigation). Representation extends to both national and international IP bodies, such as the Polish Patent Office, European Patent Office (EPO), European Union Intellectual Property Office (EUIPO), and World Intellectual Property Organization (WIPO). POLSERVICE attorneys also appear on behalf of clients before administrative, civil (IP), criminal, and arbitration courts, with several registered as representatives before the Unified Patent Court (UPC).



Beyond client representation, POLSERVICE actively contributes to shaping IP law through involvement in legislative reforms, including the draft IP Act in Poland and changes to the epi rules for European Patent Attorneys. Team members hold prominent roles in advisory and quality panels at the Polish Patent Office and EUIPO, ensuring high standards in IP practices.

POLSERVICE is deeply engaged in the global intellectual property community. Its attorneys are members of leading international intellectual property organizations, including AIPPI, INTA, ECTA, LES, UNION, MARQUES, FICPI, and epi, holding leadership or elected positions within their bodies and committees. They also represent the firm at national and international industry events, such as the BIO International Convention, and collaborate with associations like the Polish Association of Biotechnology Companies BioForum.

POLSERVICE is consistently recognized by respected cross-border IP law firm directories and rankings, such as Managing IP's IP STARS, IAM Patent 1000, IAM Strategy 300, WTR 1000, Lexology Index: Intellectual Property, Financial Times' Europe's Leading Patent Law Firms, WIPR Leaders, Chambers and Partners, and more.

Committed to innovation and security, the firm has implemented ISO/IEC 27001-certified Information Security Management System, ensuring operational integrity and client trust. The firm's computerized IP record management system allows safe and efficient handling of information.

POLSERVICE also integrates artificial intelligence into workflows, particularly for trademark searches and monitoring, as well as document review and drafting to maintain efficiency and accuracy.

QIAGEN Gdańsk sp. z o.o.

address

Trzy Lipy 3/2.58
80-172 Gdańsk
Poland

contact

GdanskOffice@qiagen.com

www

www.qiagen.com



QIAGEN Gdańsk

supports life science innovation with high-quality enzyme solutions and scalable manufacturing capabilities for research, molecular biology and biopharmaceutical applications. Drawing on QIAGEN's broader enzyme portfolio, the site contributes to workflows including PCR and DNA amplification, RNA analysis, assays and detection, cloning and DNA recombination, reaction cleanup, nucleic acid labeling, and other applications where performance, consistency and reliability matter.


For partners in biopharma, QIAGEN offers GMP-grade enzymes developed for regulated applications, supporting product purity, consistency and GMP-compliant workflows from process development to commercialization. QIAGEN highlights purpose-built GMP facilities in Gdańsk and Hilden, ISO 9001 and ISO 13485 certification, fermentation capacity up to 15,000 L, robust SOP-based production, validated equipment and analytical methods, and full traceability from raw materials to finished goods. This makes QIAGEN Gdańsk a relevant partner for organizations seeking dependable enzyme manufacturing in a quality-controlled environment.



QIAGEN ALSO SUPPORTS OEM

and custom projects for commercial customers who need scalable, reproducible products tailored to their requirements. Enzymes can be adapted through adjusted concentrations, buffer formulations, fill volumes and packaging options, with additional quality controls aligned to project needs. The portfolio spans enzymes for molecular biology applications such as DNA polymerases, RNA polymerases, reverse transcriptases, ligases, PCR and RT-PCR master mixes, modifying enzymes, binding proteins, and Proteinase K.

QIAGEN Gdańsk offers cooperation potential in two directions: access to high-quality enzymes for integration into workflows, products and commercial assays, and collaboration on development and manufacturing projects requiring scale, documentation and customization. While enzymes currently represent the largest part of the offering, the site's competencies are also relevant for recombinant protein development and manufacturing projects.



RTTechnik Zach Gmbh

address

ul. Ziębicka 35/116,
60-164 Poznań

contact

office@rttechnik.com

www

www.rttechnik.com



RTTECHNIK



RTTechnik sp. z o.o.

RTTechnik jest firmą z ponad 30-letnim doświadczeniem w projektowaniu i budowaniu pomieszczeń czystych typu cleanroom głównie dla branży farmaceutycznej i biotechnologicznej.

Dzięki ogromnemu doświadczeniu doradzamy, konsultujemy i dostosowujemy projekty do indywidualnych potrzeb klienta.

Pełnimy rolę generalnego wykonawcy, a nasi kierownicy koordynują zespoły specjalistów zapewniając profesjonalne i terminowe wdrożenia.

Projektujemy, dostarczamy kompletne instalacje, które następnie montujemy i uruchamiamy, przeprowadzamy kwalifikacje i szkolimy personel. Na życzenie klienta wykonujemy również przeglądy serwisowe.



Sieć Badawcza Łukasiewicz-PORT

address

ul. Stabłowicka 147
54-066 Wrocław

contact

laboratoria@port.lukasiewicz.gov.pl
+48 510 131 925

www

port.lukasiewicz.gov.pl



Łukasiewicz – PORT

is a modern research and development center based in Wrocław and a member of the Łukasiewicz Research Network. As one of Poland's largest research institutions, it combines interdisciplinary expertise with state-of-the-art infrastructure to advance innovation in health, biotechnology, and materials engineering. The institute supports both scientific discovery and industrial development by transforming research results into practical applications.

SERVICE PORTFOLIO / LABORATORY SERVICES


Łukasiewicz - PORT offers specialized research and analytical services to industry, healthcare organizations, and scientific institutions. Its advanced infrastructure supports cutting-edge research in biotechnology, microbiology, biomedical sciences, and materials engineering.

The institute provides access to modern facilities, including microbiology and BSL-2 diagnostic laboratories, an animal facility, and materials characterization laboratories equipped for physicochemical, biological, and bioengineering analyses.

Genetic and Microbiological Diagnostics Laboratory provides research and commercial services in laboratory diagnostics, molecular biology, and microbiology. It supports universities, research teams, and companies in the pharmaceutical, cosmetic, and industrial sectors by providing tailored analytical solutions.

SERVICES INCLUDE:

- Bioburden determination and monitoring
- Microbiological quality testing of sterile and non-sterile products
- Minimum inhibitory concentration (MIC) testing
- Assessment of antibacterial and antifungal properties of materials and polymers
- Mutagenicity and genotoxicity testing (Ames test)
- Bacterial endotoxin testing using recombinant Factor C (rFC)
- DNA extraction and microorganism identification based on 16S rRNA sequencing
- Whole genome sequencing (WGS) of microorganisms
- Gene expression analysis using RT-qPCR and digital PCR
- Microbiome profiling based on 16S rDNA sequencing
- Isolation, identification, and phenotypic characterization of microorganisms



MATERIALS AND TECHNOLOGICAL RESEARCH LABORATORY

specializes in advanced materials characterization and comprehensive analytical services. It supports scientific and industrial partners by providing in-depth analyses of pharmaceuticals, cosmetics, biomaterials, polymers, ceramics, metals, and functional materials.

Services include:

- NMR spectroscopy for the identification and quantification of organic compounds
- FTIR spectroscopy for the confirmation and identification of major functional groups
- Raman spectroscopy for studies of chemical structure and crystallinity
- ICP-OES analysis for elemental determination in solids and solutions
- X-ray diffraction (XRD) for phase identification and crystallographic structure analysis
- Thermal analysis (TGA, DSC, TMA) for evaluating thermal stability, decomposition behavior, phase transitions, and thermomechanical properties
- Microscopy (SEM, TEM, QEMSCAN) for detailed microstructural characterization and morphological investigations
- Elemental analysis (C, S) for carbon and sulfur determination

SyVento

address

ul. Za Górą 19, 32-050 Skawina,
Poland

contact

(+48) 885 855 564

e-mail:

www


syvento.com

syvento | BIO
TECH



SyVento sp. z o.o.

SyVento BioTech is an innovative biotech company focused on the development of lipid-based nanocarriers and LNP technology. With a state-of-the-art facility in Krakow, Poland, it offers end-to-end CDMO services, including formulation development and optimization, scale-up, regulatory support, and manufacturing (F&F), all while adhering to stringent cGMP quality standards. With a team of PhD-level experts, SyVento BioTech provides tailored solutions for the encapsulation and delivery of therapeutic molecules such as small molecules, RNA, DNA, and proteins. The company is strategically positioned to create customized partnerships, offering unique and comprehensive services all under one roof.



Jagiellonian University

address

Gołębia 24, 31-007 Kraków, Poland
Technology Transfer Centre (CTT
CITTRU): Bobrzyńskiego 12, Kraków,
Poland

contact

cittru@uj.edu.pl

www

www.uj.edu.pl



Company / Organization Profile

Founded in 1364, Jagiellonian University (JU) is one of Europe's oldest universities and one of Poland's leading research-intensive institutions. Its life science ecosystem includes the Jagiellonian University Medical College, the Faculty of Biochemistry, Biophysics and Biotechnology, the Małopolska Centre of Biotechnology, the Jagiellonian Centre for Experimental Therapeutics (JCET), and the National Centre for Synchrotron Radiation Research SOLARIS. The University conducts research in biotechnology, biomedicine, molecular biology, genomics, drug discovery, and translational medicine.

The University brings together multidisciplinary teams of scientists, clinicians, and industry partners to address major health and societal challenges. Research activities cover areas including molecular and cellular biology, microbiology, immunology, virology, cancer biology, regenerative medicine, computational biology, bioinformatics, omics technologies, precision medicine, antimicrobial resistance, and biotechnology applications in healthcare and industry.



Jagiellonian University offers access to state-of-the-art research infrastructure, including advanced omics platforms, structural biology facilities, synchrotron-based analytical technologies, bioinformatics resources, and specialized biomedical laboratories. The University actively participates in European and international research programs and maintains extensive collaborations with academic institutions, hospitals, pharmaceutical companies, biotechnology enterprises, and innovation ecosystems worldwide.

Through the Technology Transfer Centre CITTRU, JU supports the commercialization of research results, intellectual property protection, industry-academia partnerships, licensing activities, and the development of innovative technologies with market potential.

KEY ACHIEVEMENTS IN BIOTECHNOLOGY AND LIFE SCIENCES

- The Faculty of Biochemistry, Biophysics and Biotechnology has consistently been ranked as the leading biotechnology faculty in Poland, offering internationally recognized education and conducting high-impact research in molecular biology, genetic engineering, immunology, microbiology, biotechnology.
- Małopolska Centre of Biotechnology is leading life science research hub in Central Europe, conducting internationally recognized research in genomics, structural biology, microbiology, infectious diseases, computational biology, and translational medicine. The Centre hosts advanced research groups and participates in numerous international scientific consortia.
- Jagiellonian Centre for Experimental Therapeutics (JCET) is a multidisciplinary research centre focused on translational medicine, drug discovery, and the development of innovative therapeutic approaches.
- National Centre for Synchrotron Radiation Research SOLARIS, the largest synchrotron facility in Central and Eastern Europe, provides advanced capabilities for structural biology, drug discovery, pharmaceutical research, molecular imaging, and biomaterials characterization, supporting both academic and industrial R&D projects.
- Strong integration with Jagiellonian University Medical College enables efficient translation of scientific discoveries into clinical applications and healthcare innovations.

AREAS OF COLLABORATION

- Biotechnology and biomedical R&D
- Drug discovery and development (focus on CNS and Oncology)
- Omics technologies and bioinformatics
- Molecular diagnostics and precision medicine
- Microbiology and antimicrobial resistance
- Structural biology and synchrotron-based research
- Medical devices and healthcare innovations
- Technology transfer, licensing, and research partnerships
- Contract research and industry-academia collaboration

Jagiellonian University offers a unique environment for interdisciplinary life science research by integrating fundamental biological research, clinical expertise, advanced research infrastructure, and technology transfer capabilities within a single innovation ecosystem.



WPD Pharmaceuticals S.A.

address

Żwirki i Wigury 101, 02-089
Warszawa, Poland

contact

mariusz.olejniczak@wpdpharmaceuticals.com

www

www.wpdpharmaceuticals.com



WPD Pharmaceuticals

is a Polish biotechnology company developing innovative targeted therapies in oncology, with a focus on brain tumors and other cancers with high unmet medical need. The company holds exclusive worldwide rights to several drug candidates developed in collaboration with Wake Forest University (USA), including WPD401, a leading asset ready to enter clinical development. WPD Pharmaceuticals focuses on biological therapeutic molecules, drug delivery technologies for brain tumors and radiopharmaceutical platforms. Our business model is to advance breakthrough therapies through Phase II and to commercialize them with partnerships, licensing-out, and strategic collaborations. Through strong scientific and clinical team and smart partnerships (Mabion, Robeauté and others) we strive to deliver state of the art molecules and technology.



WPD401, a Protein-Drug Conjugate, targets four tumor-associated receptors: IL-13RA2, EphA2, EphB2 and EphA3 co-upregulated in GBM, TNBC, and other aggressive tumors; rarely co-expressed in healthy tissue. It has a high tumor specificity via recognition of a unique malignant signature, enhanced uptake & avidity through multivalent binding. WPD401 prevents antigen escape, a major limitation of single-target therapies and is effective in heterogeneous, dynamically changing tumors. It is conjugated with DM1 (mertansine) - the clinically validated payload from FDA-approved Kadcyra - which, is released directly into tumor cells, maximizing cytotoxicity while minimizing systemic toxicity.



In preparation for Phase I trial in humans, we performed a dose-limiting toxicity study in 11 dogs with spontaneous brain tumors. The treatment with WPD401 produced remarkable anti-tumor responses in these dogs with up to 95% tumor reduction observed after single treatment with our drug candidate. Treated subjects achieved long-term disease control, with sustained survival and no recurrence.

Phase I trial in recurrent glioblastoma patients should commence in Q4 2026. The main objective is to confirm safety and determine dosage for Phase II. Additionally, assess progression-free survival (PFS) at six months and overall survival (OS) as indicators of clinical activity to confirm the concept. WPD401 will be delivered directly to the brain by means of Convection-Enhanced Delivery provided by ClearPoint Neuro. Currently, this is considered the lowest-risk option because it is an FDA-approved/cleared clinical platform that has been widely used for products already on the market or in clinical trials. The study will be conducted in the US and funded by NIH grants raised in the USA, with an additional \$1 million from our capital.

YouNick Mint

address

ul. Krzemowa 1, Złotniki
62-002 Suchy Las

contact

office@younickmint.com

www

younickmint.vc



YouNick Mint

is a venture capital fund supporting technology companies at the early stages of development (pre-seed & seed). The fund is managed by a team of seasoned business practitioners, combining years of collaborative experience with deep domain expertise in two key areas:

- **Healthcare:** biotech, medtech, pharma, life sciences, and digital health.
- **Industry 4.0:** materials technology, ICT, RPA, and PropTech.

Track Record & Portfolio

Across our previous investment vehicles, YouNick has backed nearly 40 innovative startups. Our investment track record features a robust portfolio of technological ventures, encompassing active companies that are rapidly scaling sales or securing follow-on investors, alongside successfully executed strategic exits.



Current Portfolio Companies (Selected Investments):

- nuDelta - an advanced document processing automation platform (AI/RPA).
- Supersonic Food - innovative, functional food and meal replacements (clean label & performance products).
- Prosoma - a digital therapeutics (DTx) solution supporting oncology patients.
- Intelliseq - an advanced bioinformatics platform for the comprehensive management, analysis, and interpretation of genomic data.
- nCage Therapeutics - next-generation vaccines and drug delivery systems based on a proprietary VLP TRAP-cage protein scaffold platform.



Exits (Selected Exits):

- Sale of Smart Pharma to the international pharmaceutical corporation Chiesi Pharmaceutici.
- Acquisition of PozLab by the Selvita Group.
- Sale of QRTag to Polskie ePłatności.

Current Strategy & Partners

Currently, through our fourth fund, we invest between €250,000 and €1.5 million (approx. PLN 1M to PLN 8M) in forward-thinking technology companies that effectively tackle critical technological and demographic challenges.

Our investors and strategic partners include private entrepreneurs from the healthcare, IT, and real estate sectors, as well as PFR Ventures, which invested in the fund under the PFR Starter program.



Join us!
29/09/2026
Warsaw, Poland

Discover cutting-edge bio-innovations

Gain exclusive insights into the latest breakthroughs in biotechnology and green solutions. Explore how sustainable science is redefining industries and driving global change.

Connect with industry leaders & pioneers in Poland

Network with top-tier scientists, eco-entrepreneurs, and policy makers. Expand your professional circle and spark valuable collaborations during our dedicated matchmaking sessions.

Shape the Green Future


Be part of the conversation that matters. Engage in high-level discussions on bio-economy trends, regulatory shifts, and the next generation of environmental solutions.

Let's Build GreenBio Together!

Want to shape the conference with us? Contact us at info@bioforum.pl to explore partnership and speaking opportunities.

Register for free:

https://cebioforum.com/pl/greenbioforum_2026/



Save the date!
14-15 April 2027
Warsaw, Poland

bioForum
Central European

Central Europe's premier B2B partnering conference connecting biopharma leaders, deeptech innovators, and global investors to accelerate life sciences commercialization in the CEE region. Designed to bridge regional innovation with global business, the event provides a targeted platform for cross-border collaboration, dealmaking, and scaling R&D capabilities.

B2B Partnering

Connect with CEOs, VC funds, and R&D leaders from CEE & Europe

Market Insights

Discover emerging deeptech, pharma, and bio-innovations

Scalability

Find reliable supply chain and research partners in Poland



Partnering for success From R&D to Market

Central European BioForum
 info@cebioforum.com

Subscribe to
CEBioForum
Newsletter!

